ClinicalTrials.gg
CompletedNCT05850520QUASARUpdated Jun 17, 2026Results posted

A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)

A Phase 3 interventional study of Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose and Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg in Macular Edema Secondary to Retinal Vein Occlusion, sponsored by Bayer. Completed at 273 sites in 27 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-17.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
892
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies in Macular Edema by Bayer — none open to participants now, 1 under way, none of them phase 3. Macular Edema · Bayer.

Enrollment
Largest of 10
892 · median 357
Started
2023
the only one that year
Phase 3
7 of 16
none open now
Registered
13th of 16
by date

Among the 16 studies in Macular Edema by Bayer, this one has the largest enrollment of the 10 interventional ones that give a count, is the only one that started in 2023, is one of 7 in phase 3, and was the 13th registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 66 are open to participants now.

Browse Macular Edema studies →

Open to participants now

None of the 16 studies in Macular Edema by Bayer is open now. The open studies under Macular Edema, anywhere →

Who these studies take

Of the 44 Macular Edema studies recruiting now, 31 (70%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies in Macular Edema by Bayer as a file.
02

Study summary

Researchers are looking for a better way to treat people who have macular edema secondary to retinal vein occlusion (RVO).

In people with RVO, a blood vessel that carries blood away from the retina (vein) becomes blocked. The retina is the very back part of the eye. The blocked vein causes fluid and blood to leak into the retina and thereby causes a swelling of the macula (the center of the retina responsible for fine vision). This swelling is called macular edema.

When a vein in the retina is blocked, the levels of a protein called vascular endothelial growth factor (VEGF) rises. VEGF helps the growth of new blood vessels. This can lead to macular edema and may cause the vision to become blurry.

The study treatment intravitreal (IVT) aflibercept is given as an injection into the eye. It works by blocking VEGF and this can help repair vision problems related to RVO. IVT aflibercept is already available and is prescribed by doctors as the standard of care treatment for macula edema secondary to RVO. Standard of care is a treatment that medical experts consider most appropriate for a disease.

Standard of care is given every 4 weeks in people with macula edema secondary to RVO. While repeated injections of aflibercept may prevent worsening of vision, it may place a burden on the patient. However, a higher amount (8 mg) compared to the standard of care (2 mg) of IVT aflibercept is being tested in studies. This higher amount could be given less often. The amount of IVT aflibercept given is measured in milligrams, also known as mg.

The main purpose of this study is to learn how well a higher amount of the study treatment aflibercept works in people with macular edema secondary to RVO. To answer this, researchers will measure changes in vision called best corrected visual acuity (BCVA) in the study participants between study start and after 36 weeks of treatment. Changes will then be compared between those participants who received the higher amount of IVT aflibercept and those that received standard of care.

To learn how safe the study treatment is in the participants, the researchers will count the number of participants from study start and up to 64 weeks later that have:

  • adverse events
  • serious adverse events

"Adverse events" are any medical problems that the participants have during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think they might be related to the study treatments. An adverse event is considered "serious" when it leads to death, puts the participants' lives at risk, requires hospitalization, causes disability, causes a baby being born with medical problems or is otherwise medically important.

Dependent on the treatment group, the participants will either receive the higher amount of aflibercept or standard of care as an intravitreal injection for up to 60 weeks. The study will consist of a test (screening) phase, a treatment phase and an end of study phase. Each participant will be in the study for up to 64 weeks.

One visit to the study site is planned during the screening phase, followed by visits approximately every 4 weeks (16 in total) during treatment and one visit at the end of the study.

During the study, the study doctors and their team will:

  • check patients' eye health using various eye examination techniques
  • measure patients' eye vision (BCVA)
  • take blood and urine samples
  • do physical examinations
  • check vital signs
  • examine heart health using electrocardiogram (ECG)
  • do pregnancy tests in women of childbearing age

In addition, participants will be asked to fill a questionnaire on vision-related quality of life.

03

Conditions studied

  • Macular Edema Secondary to Retinal Vein Occlusion
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult ≥18 years of age (or country's legal age of adulthood if the legal age is >18 years) at the time of signing the .
  • Treatment-naïve macular edema involving the foveal center secondary to RVO (BRVO, HRVO, or CRVO) diagnosed within 16 weeks (112 days) before the screening visit in the study eye.
  • Early Treatment Diabetic Retinopathy Study BCVA letter score of 73 to 24 (20/40 to 20/320) at screening and baseline visits in the study eye.

Decrease in BCVA determined to be primarily the result of RVO in the study eye.

  • Mean CST ≥300 μm on optical coherence tomography (OCT) if excluding Bruch's membrane (e.g., Cirrus or Topcon) or ≥320 μm if including Bruch's membrane (e.g., Heidelberg Spectralis), confirmed by the reading center at the screening visit and by the site at baseline visit in the study eye.
  • Capable of giving signed informed consent form (ICF) by study participant or legally acceptable representative, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
  • US participants will be required to have a Health Insurance Portability and Accountability Act (HIPAA) authorization; in other countries, as applicable according to national laws.
  • Women of (WOCBP) or men who are sexually active with partners of childbearing potential must agree to use highly effective prior to the initial dose/start of the first treatment, during the study, and for at least 4 months after the last administration of study intervention. Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for participation in clinical studies and fulfil the conditions set on Section 10.4.2.

Exclusion criteria

Exclusion Criteria:

  • Concurrent disease that causes substantial decrease of BCVA, is expected to limit BCVA recovery or is likely to require medical or surgical intervention during the study in the study eye.
  • Presence or history of the following ocular conditions:

    1. Advanced age-related macular degeneration (neovascular AMD or geographic atrophy) in the study eye.
    2. Diabetic macular edema or diabetic retinopathy, defined in diabetic participants as diabetic retinopathy lesions outside the area of the vein occlusion in the study eye and anywhere in the retina in the fellow eye.
    3. Anterior segment neovascularization, vitreous hemorrhage, retinal detachment in the study eye.
    4. Vitreomacular traction, epiretinal membrane or structural damage to the macula that is considered by the Investigator to significantly affect central vision or preclude improvement in vision in the study eye.
    5. Macular hole of stage 2 and above in the study eye.
    6. Myopia of a spherical equivalent of at least 8 diopters prior to any refractive or cataract surgery in the study eye.
    7. Corneal transplant or corneal dystrophy in the study eye.
    8. Idiopathic or uveitis in the study or in the fellow eye.
  • Presence of the following ocular conditions at screening or baseline visit:

    1. Significant media opacities, including cataract, that interfere with BCVA, or imaging assessments (e.g., fundus photography [FP], OCT) in the study eye.
    2. Aphakia, or pseudophakia with absence of posterior capsule (unless it occurred as a result of a yttrium-aluminum-garnet [YAG] posterior capsulotomy performed more than 30 days before the screening visit), in the study eye.
    3. Uncontrolled glaucoma (defined as IOP >25 mmHg despite treatment with anti-glaucoma medication); or history or likely future need of glaucoma surgery in the study eye.
    4. Intraocular inflammation/infection (including trace, or above, cells in the anterior chamber and/or vitreous) within 12 weeks (84 days) of the screening visit in the study or in the fellow eye.
    5. Extraocular or periocular infection or inflammation (including infectious blepharitis, keratitis, scleritis, or conjunctivitis) in the study or in the fellow eye.
  • Uncontrolled blood pressure (defined as systolic >160 mmHg or diastolic >95 mmHg) at the screening visit or baseline visit.
  • Uncontrolled diabetes mellitus, defined by (HbA1c) >12% at the screening visit.
  • History of cerebrovascular accident or myocardial infarction within 24 weeks (168 days) before the screening visit or between screening and baseline visits.
  • Renal failure requiring dialysis, or renal transplant at screening or potentially during the study.
  • Any prior or concomitant ocular or systemic treatment (with an or approved, anti-VEGF or other agent) or surgery for RVO in the study eye.
  • Previous administration of systemic anti-angiogenic medications for any condition.
  • Prior treatment of the study eye with any of the following drugs (any route of ophthalmic administration) or procedures:

    1. Anti-angiogenic drugs at any time including investigational therapy (e.g., with anti-angiopoietin/anti-VEGF bispecific monoclonal antibodies).
    2. Previous use topical within 4 weeks (28 days) from the screening visit, or intraocular or periocular steroids within 16 weeks (112 days) from the screening visit, or steroid implants at any time.
    3. Previous treatment with intraocular or periocular implant, gene therapy, or cell therapy at any time.
    4. Treatment with ocriplasmin at any time.
    5. Vitreoretinal surgery (including scleral buckling) at any time.
    6. Any intraocular surgery, including cataract surgery, within 12 weeks (84 days) before the screening visit.
    7. Previous treatment with retinal laser photocoagulation.
  • Prior treatment of the fellow eye with any of the following:

    a. Gene therapy, or cell therapy in the fellow eye at any time.

  • Participation in other clinical studies requiring administration of investigational treatments (other than vitamins and minerals) at the time of screening visit, or within 30 days or 5 half-lives of administration of the previous study intervention, whichever is longer.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
892 participants (actual)

Study arms

  • Experimental
    Higher Dose Regimen 1

    Higher dose of aflibercept is administered with initial initiation doses intervals, followed by extension of treatment intervals and further adjustment of intervals according to treatment response.

    Drug: Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose · Drug: Sham · Diagnostic Test: Fluorescein

  • Experimental
    Higher Dose Regimen 2

    Higher dose of aflibercept is administered with initial initiation doses intervals, followed by extension of treatment intervals and further adjustment of intervals according to treatment response.

    Drug: Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose · Drug: Sham · Diagnostic Test: Fluorescein

  • Active comparator
    Standard of care

    Aflibercept 2 mg is administered by standard treatment intervals, followed by adjustment of treatment intervals according to treatment response.

    Drug: Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg · Diagnostic Test: Fluorescein

Interventions

  • DrugAflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose

    Intravitreally (IVT) injection.

  • DrugAflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg

    Intravitreally (IVT) injection.

  • DrugSham

    Sham procedure will be given on visits when an active injection is not planned.

  • Diagnostic testFluorescein

    Fluorescein 100 mg/mL solution for injection is a dye that makes the retinal vessels visible during FA examinations, and as such, it will be used as an auxiliary medicinal product (AxMP) in this periodic ophthalmic examination. This medicine is for diagnostic use only. It is not used to treat any condition.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in BCVA Measured by the ETDRS Letter Score at Week 36

    BCVA: Best-Corrected Visual Acuity; ETDRS: Early Treatment Diabetic Retinopathy Study; ETDRS letter score (ranging from 0 to 100 letters). A higher letter score means a better outcome (better visual acuity)

    Time frame: At Week 36

Secondary outcomes

  1. Number of Active Injections From Baseline to Week 64

    Active injections refer to the number of injections that were actually administered, as opposed to the number of planned injections.

    Time frame: From baseline to Week 64

  2. Number of Active Injections From Baseline to Week 36

    Active injections refer to the number of injections that were actually administered, as opposed to the number of planned injections.

    Time frame: From baseline to Week 36

  3. Change From Baseline in BCVA Measured by the ETDRS Letter Score at Week 44*

    BCVA: Best-Corrected Visual Acuity; ETDRS: Early Treatment Diabetic Retinopathy Study; ETDRS letter score (ranging from 0 to 100 letters). A higher letter score means a better outcome (better visual acuity). \*This endpoint was only measured for the 8q8/5 and 2q4 groups

    Time frame: At Week 44

  4. Change From Baseline in BCVA Measured by the ETDRS Letter Score at Week 64

    BCVA: Best-Corrected Visual Acuity; ETDRS: Early Treatment Diabetic Retinopathy Study; ETDRS letter score (ranging from 0 to 100 letters). A higher letter score means a better outcome (better visual acuity)

    Time frame: At Week 64

  5. Participants Gaining at Least 15 Letters in BCVA From Baseline at Weeks 36 and 64

    Time frame: From baseline at Weeks 36 and 64

  6. Participants Achieving an ETDRS Letter Score of at Least 69 (Approximate 20/40 Snellen Equivalent) at Weeks 36 and 64

    ETDRS letter score (ranging from 0 to 100 letters). A higher letter score means a better outcome (better visual acuity)

    Time frame: At Weeks 36 and 64

  7. Participants Having no Intraretinal Fluid (IRF) and no Sub-retinal Fluid (SRF) in the Center Subfield at Weeks 36 and 64

    Number of participants with no retinal fluid (no IRF and no SRF) in the central subfield at Weeks 36 and 64

    Time frame: At Weeks 36 and 64

  8. Change From Baseline in Central Sub-field Thickness (CST) at Week 36

    Time frame: From baseline to Week 36

  9. Change From Baseline in Central Sub-field Thickness (CST) at Week 64

    Time frame: From baseline to Week 64

  10. Change From Baseline in NEI VFQ 25 Total Score at Week 36

    NEI-VFQ-25: National Eye Institute Visual Functioning Questionnaire-25; The NEI VFQ-25 total score ranges from 0 to 100. A higher score means a better outcome (better patient-reported visual function).

    Time frame: From baseline to Week 36

  11. Change From Baseline in NEI VFQ 25 Total Score at Week 64

    NEI-VFQ-25: National Eye Institute Visual Functioning Questionnaire-25; The NEI VFQ-25 total score ranges from 0 to 100. A higher score means a better outcome (better patient-reported visual function).

    Time frame: From baseline at Week 64

  12. Participants Dosed Only Q8 Through Week 36 in the 8 mg Q8 Group

    Number of participants in the aflibercept 8q8/3 and the aflibercept 8q8/5 groups who were able to maintain every 8 weeks (Q8) dosing through Week 36. Only participants who did not discontinue study intervention prior to Week 36, and were therefore considered "completers" for Week 36, were included in the analysis of this endpoint.

    Time frame: Through Week 36

  13. Participant Having Last Treatment Interval ≥12 or of 16 Weeks at Week 64

    The proportion of participants having last completed treatment interval ≥12 or of 16 weeks at Week 64 for Week 64 completers.

    Time frame: At Week 64

  14. Participant Having Next Intended Interval ≥12, ≥16 or of 20 Weeks at Week 64

    The proportion of participants having last intended treatment interval ≥12, ≥16 or 20 weeks at Week 64 for Week 64 completers.

    Time frame: At Week 64

  15. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Through Weeks 36 and 64

    TEAEs were defined as AEs that occurred in the time frame from first injection (active or sham) to the last injection (active or sham) plus 30 days. Ocular TEAEs in study eye and non-ocular TEAEs are included (ocular TEAEs in fellow eye are excluded)

    Time frame: Through Weeks 36 and 64

  16. Systemic Exposure to Aflibercept as Assessed by Plasma Concentrations of Free, Adjusted Bound and Total Aflibercept From Baseline Through Weeks 36 and 64

    Total aflibercept is the sum of free and adjusted bound aflibercept.

    Time frame: From baseline through Week 36 and 64

07

Results

Posted Dec 18, 2025

Participant flow

The study was conducted at 237 centers in Europe, America, Japan, and Asia-Pacific between 15-May-2023 (first participant first visit) and 27-May-2025 (last participant last visit) (Week 64).

Participant flow — Overall Study
MilestoneAflibercept 2q4Aflibercept 8q8/3Aflibercept 8q8/5
Started301293298
Completed270268256
Not completed312542
Withdrew: Withdrawal by subject181328
Withdrew: Lost to follow-up545
Withdrew: Death325
Withdrew: Adverse event323
Withdrew: Physician decision020
Withdrew: Protocol deviation001
Withdrew: Logistical problem220

Outcome measures

PrimaryChange From Baseline in BCVA Measured by the ETDRS Letter Score at Week 36

BCVA: Best-Corrected Visual Acuity; ETDRS: Early Treatment Diabetic Retinopathy Study; ETDRS letter score (ranging from 0 to 100 letters). A higher letter score means a better outcome (better visual acuity)

Time frame:
At Week 36
Reported as:
Least squares mean · Letters
Change From Baseline in BCVA Measured by the ETDRS Letter Score at Week 36
LettersAflibercept 2q4Aflibercept 8q8/3Aflibercept 8q8/5
Change From Baseline in BCVA Measured by the ETDRS Letter Score at Week 3617.5 ± 0.717.4 ± 0.718.3 ± 0.6
Statistical analysis
  • Aflibercept 2q4 vs Aflibercept 8q8/3 · Mixed Models Analysis · p = <0.0001 (1-sided p-value.) · Difference in ls means: -0.1 · 95% CI -2.0 to 1.9Estimation mainly based on hypothetical strategy, i.e. observed data beyond intercurrent events (premature discontinuation of treatment, prohibited medication, missing injection) were censored. Missing/censored data was handled implicitly by MMRM.
  • Aflibercept 2q4 vs Aflibercept 8q8/5 · Mixed Models Analysis · p = <0.0001 (1-sided p-value.) · Difference in ls means: 0.8 · 95% CI -1.1 to 2.7Estimation mainly based on hypothetical strategy, i.e. observed data beyond intercurrent events (premature discontinuation of treatment, prohibited medication, missing injection) were censored. Missing/censored data was handled implicitly by MMRM.
SecondaryNumber of Active Injections From Baseline to Week 64

Active injections refer to the number of injections that were actually administered, as opposed to the number of planned injections.

Time frame:
From baseline to Week 64
Reported as:
Least squares mean · Number of active injections
Number of Active Injections From Baseline to Week 64
Number of active injectionsAflibercept 2q4Aflibercept 8q8/3Aflibercept 8q8/5
Number of Active Injections From Baseline to Week 6411.7 ± 0.18.5 ± 0.19.5 ± 0.1
Statistical analysis
  • Aflibercept 2q4 vs Aflibercept 8q8/3 · ANCOVA · p = <0.0001 (p-value based on a non-parametric rank ANCOVA applied to each imputed dataset and combined using Rubin's rule.) · Difference in ls means: -3.2 · 95% CI -3.5 to -3.0Estimation based on composite strategy for premature treatment discontinuation due to treatment related AEs and hypothetical strategy for premature treatment discontinuation due to other reasons. Hypothetical values imputed using a MI model.
  • Aflibercept 2q4 vs Aflibercept 8q8/5 · ANCOVA · p = <0.0001 (p-value based on a non-parametric rank ANCOVA applied to each imputed dataset and combined using Rubin's rule) · Difference in ls means: -2.2 · 95% CI -2.4 to -2.0Estimation based on composite strategy for premature treatment discontinuation due to treatment related AEs and hypothetical strategy for premature treatment discontinuation due to other reasons. Hypothetical values imputed using a MI model.
SecondaryNumber of Active Injections From Baseline to Week 36

Active injections refer to the number of injections that were actually administered, as opposed to the number of planned injections.

Time frame:
From baseline to Week 36
Reported as:
Least squares mean · Number of active injections
Number of Active Injections From Baseline to Week 36
Number of active injectionsAflibercept 2q4Aflibercept 8q8/3Aflibercept 8q8/5
Number of Active Injections From Baseline to Week 368.8 ± 0.06.1 ± 0.06.9 ± 0.0
Statistical analysis
  • Aflibercept 2q4 vs Aflibercept 8q8/3 · ANCOVA · p = <0.0001 (Nominal p-value based on a non-parametric rank ANCOVA adjusted for baseline BCVA, baseline CST, and the stratification variables.) · Difference in ls means: -2.7 · 95% CI -2.8 to -2.6Estimation based on composite strategy for premature treatment discontinuation due to treatment related AEs and hypothetical strategy for premature treatment discontinuation due to other reasons. Hypothetical values imputed using a MI model.
  • Aflibercept 2q4 vs Aflibercept 8q8/5 · ANCOVA · p = <0.0001 (Nominal p-value based on a non-parametric rank ANCOVA adjusted for baseline BCVA, baseline CST, and the stratification variables.) · Difference in ls means: -1.8 · 95% CI -1.9 to -1.7Estimation based on composite strategy for premature treatment discontinuation due to treatment related AEs and hypothetical strategy for premature treatment discontinuation due to other reasons. Hypothetical values imputed using a MI model.
SecondaryChange From Baseline in BCVA Measured by the ETDRS Letter Score at Week 44*

BCVA: Best-Corrected Visual Acuity; ETDRS: Early Treatment Diabetic Retinopathy Study; ETDRS letter score (ranging from 0 to 100 letters). A higher letter score means a better outcome (better visual acuity). \*This endpoint was only measured for the 8q8/5 and 2q4 groups

Time frame:
At Week 44
Reported as:
Least squares mean · Letters
Change From Baseline in BCVA Measured by the ETDRS Letter Score at Week 44*
LettersAflibercept 2q4Aflibercept 8q8/5
Change From Baseline in BCVA Measured by the ETDRS Letter Score at Week 44*17.8 ± 0.718.8 ± 0.7
Statistical analysis
  • Aflibercept 2q4 vs Aflibercept 8q8/5 · Mixed Models Analysis · p = <0.0001 (Nominal 1-sided p-value.) · Difference in ls means: 1.0 · 95% CI -1.0 to 2.9Estimation mainly based on hypothetical strategy, i.e. observed data beyond intercurrent events (premature discontinuation of treatment, prohibited medication, missing injection) were censored. Missing/censored data was handled implicitly by MMRM.
SecondaryChange From Baseline in BCVA Measured by the ETDRS Letter Score at Week 64

BCVA: Best-Corrected Visual Acuity; ETDRS: Early Treatment Diabetic Retinopathy Study; ETDRS letter score (ranging from 0 to 100 letters). A higher letter score means a better outcome (better visual acuity)

Time frame:
At Week 64
Reported as:
Least squares mean · Letters
Change From Baseline in BCVA Measured by the ETDRS Letter Score at Week 64
LettersAflibercept 2q4Aflibercept 8q8/3Aflibercept 8q8/5
Change From Baseline in BCVA Measured by the ETDRS Letter Score at Week 6417.3 ± 0.817.8 ± 0.718.1 ± 0.8
Statistical analysis
  • Aflibercept 2q4 vs Aflibercept 8q8/3 · Mixed Models Analysis · p = <0.0001 (Nominal 1-sided p-value.) · Difference in ls means: 0.5 · 95% CI -1.6 to 2.7Estimation mainly based on hypothetical strategy, i.e. observed data beyond intercurrent events (premature discontinuation of treatment, prohibited medication, missing injection) were censored. Missing/censored data was handled implicitly by MMRM.
  • Aflibercept 2q4 vs Aflibercept 8q8/5 · Mixed Models Analysis · p = <0.0001 (Nominal 1-sided p-value.) · Difference in ls means: 0.7 · 95% CI -1.5 to 2.9Estimation mainly based on hypothetical strategy, i.e. observed data beyond intercurrent events (premature discontinuation of treatment, prohibited medication, missing injection) were censored. Missing/censored data was handled implicitly by MMRM.
SecondaryParticipants Gaining at Least 15 Letters in BCVA From Baseline at Weeks 36 and 64
Time frame:
From baseline at Weeks 36 and 64
Reported as:
Count of participants · Participants
Participants Gaining at Least 15 Letters in BCVA From Baseline at Weeks 36 and 64
ParticipantsAflibercept 2q4Aflibercept 8q8/3Aflibercept 8q8/5
Number of participants who gained at least 15 letters in BCVA at Week 36158153161
Number of participants who gained at least 15 letters in BCVA at Week 64154156161
SecondaryParticipants Achieving an ETDRS Letter Score of at Least 69 (Approximate 20/40 Snellen Equivalent) at Weeks 36 and 64

ETDRS letter score (ranging from 0 to 100 letters). A higher letter score means a better outcome (better visual acuity)

Time frame:
At Weeks 36 and 64
Reported as:
Count of participants · Participants
Participants Achieving an ETDRS Letter Score of at Least 69 (Approximate 20/40 Snellen Equivalent) at Weeks 36 and 64
ParticipantsAflibercept 2q4Aflibercept 8q8/3Aflibercept 8q8/5
Participants who achieved letter score of at least 69 letters at Week 36179189189
Participants who achieved letter score of at least 69 letters at Week 64179178181
SecondaryParticipants Having no Intraretinal Fluid (IRF) and no Sub-retinal Fluid (SRF) in the Center Subfield at Weeks 36 and 64

Number of participants with no retinal fluid (no IRF and no SRF) in the central subfield at Weeks 36 and 64

Time frame:
At Weeks 36 and 64
Reported as:
Count of participants · Participants
Participants Having no Intraretinal Fluid (IRF) and no Sub-retinal Fluid (SRF) in the Center Subfield at Weeks 36 and 64
ParticipantsAflibercept 2q4Aflibercept 8q8/3Aflibercept 8q8/5
Participants with no IRF and no SRF in central subfield at Week 36221211202
Participants with no IRF and no SRF in central subfield at Week 64167193171
SecondaryChange From Baseline in Central Sub-field Thickness (CST) at Week 36
Time frame:
From baseline to Week 36
Reported as:
Least squares mean · μm
Change From Baseline in Central Sub-field Thickness (CST) at Week 36
μmAflibercept 2q4Aflibercept 8q8/3Aflibercept 8q8/5
Change From Baseline in Central Sub-field Thickness (CST) at Week 36-370.8 ± 3.9-370.9 ± 3.1-369.5 ± 2.3
Statistical analysis
  • Aflibercept 2q4 vs Aflibercept 8q8/3 · Mixed Models Analysis · p = 0.9804 (Nominal p-value for the two-sided test.) · Difference in ls means: -0.1 · 95% CI -10.0 to 9.8Estimation mainly based on hypothetical strategy, i.e. observed data beyond ICE (premature discontinuation of treatment, prohibited medication, missing injection) were censored. Missing/censored data was handled implicitly by MMRM.
  • Aflibercept 2q4 vs Aflibercept 8q8/5 · Mixed Models Analysis · p = 0.7863 (Nominal p-value for the two-sided test.) · Difference in ls means: 1.2 · 95% CI -7.7 to 10.2Estimation mainly based on hypothetical strategy, i.e. observed data beyond ICE (premature discontinuation of treatment, prohibited medication, missing injection) were censored. Missing/censored data was handled implicitly by MMRM.
SecondaryChange From Baseline in Central Sub-field Thickness (CST) at Week 64
Time frame:
From baseline to Week 64
Reported as:
Least squares mean · μm
Change From Baseline in Central Sub-field Thickness (CST) at Week 64
μmAflibercept 2q4Aflibercept 8q8/3Aflibercept 8q8/5
Change From Baseline in Central Sub-field Thickness (CST) at Week 64-353.7 ± 5.2-361.1 ± 4.3-353.3 ± 4.1
Statistical analysis
  • Aflibercept 2q4 vs Aflibercept 8q8/3 · Mixed Models Analysis · p = 0.2779 (Nominal p-value for the two-sided test.) · Difference in ls means: -7.4 · 95% CI -20.7 to 5.9Estimation mainly based on hypothetical strategy, i.e. observed data beyond ICE (premature discontinuation of treatment, prohibited medication, missing injection) were censored. Missing/censored data was handled implicitly by MMRM.
  • Aflibercept 2q4 vs Aflibercept 8q8/5 · Mixed Models Analysis · p = 0.9455 (Nominal p-value for the two-sided test.) · Difference in ls means: 0.5 · 95% CI -12.6 to 13.5Estimation mainly based on hypothetical strategy, i.e. observed data beyond ICE (premature discontinuation of treatment, prohibited medication, missing injection) were censored. Missing/censored data was handled implicitly by MMRM.
SecondaryChange From Baseline in NEI VFQ 25 Total Score at Week 36

NEI-VFQ-25: National Eye Institute Visual Functioning Questionnaire-25; The NEI VFQ-25 total score ranges from 0 to 100. A higher score means a better outcome (better patient-reported visual function).

Time frame:
From baseline to Week 36
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in NEI VFQ 25 Total Score at Week 36
Scores on a scaleAflibercept 2q4Aflibercept 8q8/3Aflibercept 8q8/5
Change From Baseline in NEI VFQ 25 Total Score at Week 366.27 ± 0.675.91 ± 0.616.92 ± 0.63
Statistical analysis
  • Aflibercept 2q4 vs Aflibercept 8q8/3 · ANCOVA · p = 0.6869 (Nominal p-value for the two-sided test.) · Difference in ls means: -0.36 · 95% CI -2.1 to 1.40Estimation mainly based on hypothetical strategy, i.e. observed data beyond ICE (premature discontinuation of treatment, prohibited medication, missing active injection) were censored. Missing/censored data was imputed by LOCF approach.
  • Aflibercept 2q4 vs Aflibercept 8q8/5 · ANCOVA · Difference in ls means: 0.65 · 95% CI -1.2 to 2.45Estimation mainly based on hypothetical strategy, i.e. observed data beyond ICE (premature discontinuation of treatment, prohibited medication, missing active injection) were censored. Missing/censored data was imputed by LOCF approach.
SecondaryChange From Baseline in NEI VFQ 25 Total Score at Week 64

NEI-VFQ-25: National Eye Institute Visual Functioning Questionnaire-25; The NEI VFQ-25 total score ranges from 0 to 100. A higher score means a better outcome (better patient-reported visual function).

Time frame:
From baseline at Week 64
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in NEI VFQ 25 Total Score at Week 64
Scores on a scaleAflibercept 2q4Aflibercept 8q8/3Aflibercept 8q8/5
Change From Baseline in NEI VFQ 25 Total Score at Week 647.21 ± 0.606.10 ± 0.666.67 ± 0.63
Statistical analysis
  • Aflibercept 2q4 vs Aflibercept 8q8/3 · ANCOVA · p = 0.2167 (Nominal p-value for the two-sided test.) · Difference in ls means: -1.11 · 95% CI -2.9 to 0.65Estimation mainly based on hypothetical strategy, i.e. observed data beyond ICE (premature discontinuation of treatment, prohibited medication, missing active injection) were censored. Missing/censored data was imputed by LOCF approach.
  • Aflibercept 2q4 vs Aflibercept 8q8/5 · ANCOVA · p = 0.5340 (Nominal p-value for the two-sided test.) · Difference in ls means: -0.54 · 95% CI -2.30 to 1.17Estimation mainly based on hypothetical strategy, i.e. observed data beyond ICE (premature discontinuation of treatment, prohibited medication, missing active injection) were censored. Missing/censored data was imputed by LOCF approach.
SecondaryParticipants Dosed Only Q8 Through Week 36 in the 8 mg Q8 Group

Number of participants in the aflibercept 8q8/3 and the aflibercept 8q8/5 groups who were able to maintain every 8 weeks (Q8) dosing through Week 36. Only participants who did not discontinue study intervention prior to Week 36, and were therefore considered "completers" for Week 36, were included in the analysis of this endpoint.

Time frame:
Through Week 36
Reported as:
Count of participants · Participants
Participants Dosed Only Q8 Through Week 36 in the 8 mg Q8 Group
ParticipantsAflibercept 8q8/3Aflibercept 8q8/5All Aflibercept 8 mg
Participants Dosed Only Q8 Through Week 36 in the 8 mg Q8 Group246255501
SecondaryParticipant Having Last Treatment Interval ≥12 or of 16 Weeks at Week 64

The proportion of participants having last completed treatment interval ≥12 or of 16 weeks at Week 64 for Week 64 completers.

Time frame:
At Week 64
Reported as:
Count of participants · Participants
Participant Having Last Treatment Interval ≥12 or of 16 Weeks at Week 64
ParticipantsAflibercept 2q4Aflibercept 8q8/3Aflibercept 8q8/5
Last completed dosing interval ≥Q12183219201
Last completed dosing interval Q16—151—
SecondaryParticipant Having Next Intended Interval ≥12, ≥16 or of 20 Weeks at Week 64

The proportion of participants having last intended treatment interval ≥12, ≥16 or 20 weeks at Week 64 for Week 64 completers.

Time frame:
At Week 64
Reported as:
Count of participants · Participants
Participant Having Next Intended Interval ≥12, ≥16 or of 20 Weeks at Week 64
ParticipantsAflibercept 2q4Aflibercept 8q8/3Aflibercept 8q8/5
Last intended dosing interval ≥Q12210232219
Last intended dosing interval ≥Q16135173159
Last intended dosing interval Q20—109—
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Through Weeks 36 and 64

TEAEs were defined as AEs that occurred in the time frame from first injection (active or sham) to the last injection (active or sham) plus 30 days. Ocular TEAEs in study eye and non-ocular TEAEs are included (ocular TEAEs in fellow eye are excluded)

Time frame:
Through Weeks 36 and 64
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Through Weeks 36 and 64
ParticipantsAflibercept 2q4Aflibercept 8q8/3Aflibercept 8q8/5All Aflibercept HD
Number of participants with TEAEs at Week 36188184176360
Number of participants with TESAEs at Week 3632232649
Number of participants with TEAEs at Week 64226220211431
Number of participants with TESAEs at Week 6444373875
SecondarySystemic Exposure to Aflibercept as Assessed by Plasma Concentrations of Free, Adjusted Bound and Total Aflibercept From Baseline Through Weeks 36 and 64

Total aflibercept is the sum of free and adjusted bound aflibercept.

Time frame:
From baseline through Week 36 and 64
Reported as:
Geometric mean · ng/mL
Systemic Exposure to Aflibercept as Assessed by Plasma Concentrations of Free, Adjusted Bound and Total Aflibercept From Baseline Through Weeks 36 and 64
ng/mLAflibercept 2q4Aflibercept 8q8/3Aflibercept 8q8/5
Week 491.6 ± 55.82281.8 ± 52.16270.7 ± 63.78
Week 12151.5 ± 56.99451.7 ± 58.83452.6 ± 57.04
Week 16241.6 ± 48.33470.5 ± 58.24728.0 ± 43.80
Week 24164.1 ± 61.42179.1 ± 73.00202.5 ± 80.94
Week 36176.4 ± 63.65373.9 ± 61.16356.9 ± 71.10
Week 64NA ± NA197.5 ± 123.3387.4 ± 145.01

Adverse events

Collected over Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aflibercept 2q43/301 (1%)44/301 (14.6%)226/301 (75.1%)
Aflibercept 8q8/32/293 (0.7%)37/293 (12.6%)220/293 (75.1%)
Aflibercept 8q8/55/298 (1.7%)38/298 (12.8%)211/298 (70.8%)
All Aflibercept 8mg7/591 (1.2%)75/591 (12.7%)431/591 (72.9%)
Most frequent serious events
Showing 10 of 223
Most frequent serious events
EventAflibercept 2q4Aflibercept 8q8/3Aflibercept 8q8/5All Aflibercept 8mg
EndophthalmitisInfections and infestations3/3011/2930/2981/591
BradycardiaCardiac disorders0/3012/2930/2982/591
DiverticulitisInfections and infestations0/3012/2930/2982/591
SepsisInfections and infestations0/3012/2930/2982/591
BradycardiaCardiac disorders0/3012/2930/2982/591
DiverticulitisInfections and infestations0/3012/2931/2983/591
PneumoniaInfections and infestations2/3012/2931/2983/591
SepsisInfections and infestations0/3012/2931/2983/591
Macular holeEye disorders2/3010/2930/2980/591
EndophthalmitisInfections and infestations2/3011/2930/2981/591
Most frequent other events
Showing 10 of 1,117
Most frequent other events
EventAflibercept 2q4Aflibercept 8q8/3Aflibercept 8q8/5All Aflibercept 8mg
HypertensionVascular disorders15/30131/29325/29856/591
NasopharyngitisInfections and infestations20/30125/29327/29852/591
HypertensionVascular disorders10/30119/29320/29839/591
Intraocular pressure increasedInvestigations8/30119/29316/29835/591
CataractEye disorders17/30111/29317/29828/591
Intraocular pressure increasedInvestigations5/30116/29315/29831/591
Visual acuity reducedEye disorders11/30116/2938/29824/591
COVID-19Infections and infestations8/30116/29312/29828/591
NasopharyngitisInfections and infestations9/30115/29314/29829/591
Conjunctival haemorrhageEye disorders8/30114/29312/29826/591

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Aflibercept 2q4Aflibercept 8q8/3Aflibercept 8q8/5Total
Mean65.9 ± 11.765.8 ± 11.565.8 ± 11.565.9 ± 11.6
Sex: Female, Male
Sex: Female, Male(Participants)Aflibercept 2q4Aflibercept 8q8/3Aflibercept 8q8/5Total
Female144136146426
Male157157152466
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Aflibercept 2q4Aflibercept 8q8/3Aflibercept 8q8/5Total
Hispanic or Latino22251461
Not Hispanic or Latino267254273794
Unknown or Not Reported12141137
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Aflibercept 2q4Aflibercept 8q8/3Aflibercept 8q8/5Total
American Indian or Alaskan Native0022
Asian1019197289
Black or African American87924
Multiple1012
Native Hawaiian or other Pacific Islander0011
Not reported13221146
White178173177528
08

Study locations

273 sites
  • Retina Consultants of Orange County - Fullerton
    Fullerton, California 92835, United States
  • South Coast Retina - Long Beach
    Long Beach, California 90807, United States
  • Northern California Retina Vitreous Associates - Mountain View Office
    Mountain View, California 94040, United States
  • Desert Retina Consultants - Palm Springs Office
    Palm Springs, California 92262, United States
  • Azul Vision Pasadena
    Pasadena, California 91107, United States
  • Retina Consultants of Southern California
    Redlands, California 92374, United States
  • Retina Consultants of Southern Colorado, PC
    Colorado Springs, Colorado 80909, United States
  • New England Retina Associates
    New London, Connecticut 06320, United States
  • Rand Eye Institute
    Deerfield Beach, Florida 33064, United States
  • National Ophthalmic Research Institute - Fort Myers
    Fort Myers, Florida 33912, United States
  • The Eye Institute of West Florida - Largo
    Largo, Florida 33770, United States
  • Florida Eye Associates - Melbourne Main Office
    Melbourne, Florida 32901, United States
  • Florida Retina Institute - Orlando
    Orlando, Florida 32806, United States
  • Retina Specialty Institute - Pensacola
    Pensacola, Florida 32503, United States
  • Fort Lauderdale Eye Institute
    Plantation, Florida 33324, United States
  • Retina Vitreous Associates of Florida - Saint Petersburg
    St. Petersburg, Florida 33711, United States
  • East Florida Eye Institute
    Stuart, Florida 34994, United States
  • Center for Retina and Macular Disease - Winter Haven
    Winter Haven, Florida 33880, United States
  • Marietta Eye Clinic
    Marietta, Georgia 30060, United States
  • Retina Associates - Elmhurst
    Elmhurst, Illinois 60126, United States
  • University Retina and Macula Associates - Oak Forest
    Oak Forest, Illinois 60452, United States
  • Retina Associates - Lenexa
    Lenexa, Kansas 66215, United States
  • The Retina Care Center - Baltimore
    Baltimore, Maryland 21209, United States
  • Cumberland Valley Retina Consultants | Hagerstown, MD
    Hagerstown, Maryland 21740, United States
  • Mid Atlantic Retina Specialists - Hagerstown
    Hagerstown, Maryland 21740, United States
  • Vitreo-Retinal Associates - Worcester
    Grand Rapids, Michigan 49525, United States
  • RCM - St. Louis Park Retina Clinic
    Saint Louis Park, Minnesota 55416, United States
  • Retina Consultants of Nevada - Summerlin
    Las Vegas, Nevada 89144, United States
  • Retina Center of New Jersey
    Bloomfield, New Jersey 07003, United States
  • NJ Retina - New Brunswick
    New Brunswick, New Jersey 08901, United States
  • NJ Retina | Teaneck
    Teaneck, New Jersey 07666, United States
  • Vision Research Center
    Albuquerque, New Mexico 87109, United States
  • Vitreoretinal Consultants of NY - Great Neck
    Great Neck, New York 11021, United States
  • Vitreoretinal Consultants of NY - Hauppauge
    Hauppauge, New York 11788, United States
  • Ophthalmic Consultants of Long Island
    Lynbrook, New York 11563, United States
  • Retina Associates of Western New York
    Rochester, New York 14620, United States
  • Cincinnati Eye Institute - Blue Ash
    Blue Ash, Ohio 45242, United States
  • Midwest Retina - Main Office
    Dublin, Ohio 43016, United States
  • Retina Consultants, LLC
    Salem, Oregon 97302, United States
  • Mid Atlantic Retina - Bethlehem
    Bethlehem, Pennsylvania 18107, United States
  • Mid Atlantic Retina - Philadelphia / Wills Eye Hospital
    Philadelphia, Pennsylvania 19107, United States
  • Palmetto Retina Center, LLC - Florence
    Florence, South Carolina 29501, United States
  • Retina Consultants of South Carolina - Ladson
    Ladson, South Carolina 29456, United States
  • Charles Retina Specialists - Germantown
    Memphis, Tennessee 38119, United States
  • Austin Retina Associates - Central
    Austin, Texas 78705, United States
  • Retina Consultants of Texas - Bellaire
    Bellaire, Texas 77401, United States
  • Texas Retina Associates - Fort Worth
    Fort Worth, Texas 76104, United States
  • Medical Center Ophthalmology Associates - Northwest
    San Antonio, Texas 78240, United States
  • Retina Consultants of Texas - San Antonio Medical Center
    San Antonio, Texas 78240, United States
  • Rocky Mountain Retina Consultants - Main Office
    Salt Lake City, Utah 84107, United States
  • The Retina Group of Washington - Fairfax
    Fairfax, Virginia 22031, United States
  • Spokane Eye Clinical Research - South Hill / Downtown
    Spokane, Washington 99204, United States
  • UW Health Carbone Cancer Center
    Madison, Wisconsin 53792, United States
  • Eyeclinic Albury Wodonga
    Albury, New South Wales 2640, Australia
  • Marsden Eye Surgery Center
    Parramatta, New South Wales 2150, Australia
  • Strathfield Retina Clinic
    Strathfield, New South Wales 2135, Australia
  • Sydney Eye Hospital
    Sydney, New South Wales 2000, Australia
  • Sydney Retina Clinic
    Sydney, New South Wales 2000, Australia
  • Sydney West Retina Pty Ltd
    Westmead, New South Wales 2145, Australia
  • Adelaide Eye and Retina Centre
    Adelaide, South Australia 5000, Australia
  • Hobart Eye Surgeons
    Hobart, Tasmania 7000, Australia
  • Centre for Eye Research
    East Melbourne, Victoria 3002, Australia
  • Lion Eye Institute
    Nedlands, Western Australia 6009, Australia
  • Universitätsklinikum AKH Wien
    Vienna, State of Vienna 1090, Austria
  • Hanusch-Krankenhaus Wien
    Vienna, State of Vienna 1140, Austria
  • Medizinische Universität Graz
    Graz, Styria 8036, Austria
  • Klinikum Klagenfurt am Wörthersee
    Linz, Upper Austria 4010, Austria
  • Konventhospital Barmherzige Brüder Linz
    Linz, Upper Austria 4020, Austria
  • SEHAT Pentagram
    Sofia, Sofia City Province 1309, Bulgaria
  • Specialized Hospital For Active Treatment of Eye Diseases Zora
    Sofia, Sofia City Province 1784, Bulgaria
  • Spec. Hosp. of Ophthalm. Disease for Active Treatment Varna
    Varna, Varna Province 9000, Bulgaria
  • The Second Affiliated Hospital of Anhui Medical University
    Hefei, Anhui 230601, China
  • Beijing Aier Intech Eye Hospital
    Beijing, Beijing Municipality 100000, China
  • China-Japan Friendship Hospital
    Beijing, Beijing Municipality 100029, China
  • Peking University First Hospital - Oncology Department
    Beijing, Beijing Municipality 100034, China
  • Capital Medical University (CMU) - Beijing Tongren Hospital
    Beijing, Beijing Municipality 100062, China
  • Beijing Hospital
    Beijing, Beijing Municipality 100730, China
  • Peking Union Medical College Hospital CAMS
    Beijing, Beijing Municipality 100730, China
  • Chongqing Aier Ophthalmology Hospital
    Chongqing, Chongqing Municipality 400020, China
  • Lanzhou University - The Second Hospital (The Second Clinical Medical College of Lanzhou University)
    Lanzhou, Gansu 730030, China
  • Guangzhou Aier Eye Hospital
    Guangzhou, Guangdong 634050, China
  • Hebei eye hospital
    Hebei, Hebei 050010, China
  • Shijiazhuang General Hospital
    Shijiazhuang, Hebei 050000, China
  • Henan Provincial Eye Hospital
    Henan, Henan 450008, China
  • Tongji Hosp. of Tongji Med Coll, Huazhong Uni of Sci & Tech.
    Wuhan, Hubei 430030, China
  • Eye Center of the second Bethune Hospital, jinlin University
    Changchun, Jilin 130022, China
  • Aier Eye Hospital (LIAONING)
    Shenyang, Liaoning 110003, China
  • The Fourth People's Hospital of Shenyang
    Shenyang, Liaoning 110082, China
  • People's Hospital of Ningxia Hui Autonomous Region - Opthalmology
    Ningxia, Ningxia 750002, China
  • Qilu Hosp., Shandong Univ.
    Jinan, Shandong 250012, China
  • Shanxi Eye Hospital
    Shanxi, Shanxi 030002, China
  • Aier Eye Hospital (Chengdu)
    Chengdu, Sichuan 610093, China
  • Tianjin Medical University Eye Hospital
    Tianjin, Tianjin Municipality 300384, China
  • ZheJiang Provincial People's Hospital
    Hangzhou, Zhejiang 310014, China
  • Dongyang People's Hospital
    Jinhua, Zhejiang 322199, China
  • Fakultní Nemocnice Hradec Kralové
    Hradec Králové, 500 05, Czechia
  • Fakultní nemocnice Ostrava
    Ostrava, 708 52, Czechia
  • Nemocnice Pardubickeho kraje, a.s., Pardubicka nemocnice
    Pardubice, 530 03, Czechia
  • Fakultní nemocnice Královské Vinohrady - Urologická klinikay
    Prague, 10034, Czechia
  • Všeobecná fakultní nemocnice v Praze
    Prague, 12808, Czechia

Showing the first 100 of 273 sites across 27 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Nov 2024, 17 months.

Results were first posted in Dec 2025, 1 year 1 month after primary completion.

Of 52 industry-sponsored phase 3 interventional studies under Macular Edema, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 33. This study's 17 months is below that.

Counting every sponsor, half of 65 studies reached it within 25 months; a quarter within 18 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2023
First posted
May 9, 2023
StartActual
May 15, 2023
Primary completionActual
Nov 7, 2024
CompletionActual
May 27, 2025
Results first posted
Dec 18, 2025
Last update
Jun 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05850520
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
May 9, 2023
Start date
May 15, 2023
Primary completion
Nov 7, 2024
Completion
May 27, 2025
Results posted
Dec 18, 2025
Last update
Jun 17, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion